Alchemedicine Entered into an Exclusive License Agreement with Asahi Kasei Pharma for Endothelin A Receptor Antagonist to Treat Chronic Kidney Disease
Shots:
- Alchemedicine to receive ~$5.35B up front & is eligible to receive development, regulatory & commercial milestones along with royalty. The companies collaborated to develop & commercialize Alchemedicine’s selective Endothelin A receptor antagonist which is currently in the preclinical stage
- Kasei Pharma obtains an exclusive right globally to develop and commercialize selective Endothelin A receptor antagonist
- The selective endothelin A receptor antagonist is a small molecule that was developed from Alchemedicine’s HiSAP1 platform for a variety of difficult-to-control refractory diseases incl. CKD & demonstrated potent inhibition & high selectivity as well as exceptional efficacy in animal models of CKD
Ref: Asahi Kasei Pharma | Image: Alchemedicine
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
